Zhanguo Li
Peking University Institute of Rheuamotology and Immunology
9
8
1
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Robert B Innis, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Hamid Gourabi, PhD
head of Royan Institute
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Hillary Overholser
Zimmer Biomet
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Alan Kivitz, MD
Altoona Center for Clinical Research
Shared therapeutic areas:
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Shared therapeutic areas:
Worked with same sponsors:
Urielle Desalbres
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
Effect of Butyrate Supplement on Rheumatoid Arthritis
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus
All 9 trials loaded